Related Experiment Videos
Polymeric delivery of the active isomer of misoprostol reduces systemic availability and uterotonic activity
G W Gullikson1, R F Loeffler, D V Mehrotra
1Department of Neurological Diseases Research, G. D. Searle and Co., Skokie, Illinois, USA.
Abstract:
SC-30249 is the active isomer of misoprostol responsible for its mucosal protective effects against nonsteroidal anti-inflammatory drugs (NSAIDS). Linkage of SC-30249 to a polybutadiene polymer results in a delivery system (SC-55307) that releases the active component only under the acidic conditions of the stomach. This approach could be used to minimize side effects and systemic availability of synthetic prostaglandins. These studies were done to determine whether uterotonic activity could be recorded after treatment with SC-55307. Female beagles were implanted with uterine strain gauge force transducers, allowed 10 days for recovery and treated with estrogen to sensitize the uterus to the actions of prostaglandins. Base-line responses were determined with SC-30249, i.v., and then a randomized series of four treatments were given: SC-30249, IG, 10 micrograms/kg; SC-55307, IG, equivalent to 30 and 100 micrograms/kg of SC-30249; and a blank polymer control. HCI was given IG to provide an acid environment in the stomach, uterine responses were obtained for up to 4 h and plasma concentrations of SC-30249 free acid was determined. No uterotonic effect was seen after a low dose of SC-55307, whereas the high dose caused a brief but statistically significant increase equal to 8.8% and 17.8% of the responses to SC-30249, i.v. and IG, respectively. Peak plasma levels of SC-30249 free acid were 176.4 +/- 17.4 and 59.5 +/- 10.6 pg/ml after SC-30249, i.v. and IG, respectively, but were only 3.9 +/- 1.7 and 15.5 +/- 6.6 pg/ml after low and high doses of SC-55307, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Insights
SC-55307, a novel delivery system for misoprostol
Area of Science:
- Pharmacology
- Gastroenterology
- Reproductive Endocrinology
Background:
- SC-30249, the active isomer of misoprostol, provides mucosal protection against NSAIDs.
- A novel polymer-linked delivery system, SC-55307, releases SC-30249 under acidic stomach conditions.
- This targeted delivery aims to minimize side effects and systemic exposure of synthetic prostaglandins.
Purpose of the Study:
- To evaluate the uterotonic activity of SC-55307, a prostaglandin delivery system.
- To assess potential prostaglandin-related side effects on uterine activity.
- To compare uterotonic responses to SC-55307 versus free SC-30249.
Main Methods:
- Female beagles were surgically fitted with uterine strain gauge force transducers.
- Estrogen treatment sensitized the uterus to prostaglandin effects.
- Uterine responses to intravenous SC-30249, oral SC-30249, and oral SC-55307 (low and high doses) were measured.
Main Results:
- A high dose of SC-55307 induced a brief, statistically significant increase in uterine activity (8.8-17.8% of SC-30249 response).
- Low-dose SC-55307 showed no significant uterotonic effect.
- Peak plasma concentrations of SC-30249 free acid were substantially lower with SC-55307 compared to free SC-30249 administration.
Conclusions:
- SC-55307 demonstrates minimal uterotonic activity, suggesting reduced systemic prostaglandin effects.
- The polymer-linked delivery system effectively limits systemic availability of SC-30249.
- SC-55307 shows potential for targeted mucosal protection with a favorable side effect profile.